
    
      Groups 1:Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially
      Resectable Gastric Cancer With Liver Metastasis.

      Groups 2:Capecitabine Plus Oxaliplatin With placebo in Patients With Potentially Resectable
      Gastric Cancer With Liver Metastasis.

      Group 1 compare with Group 2 in disease-free survival time. Stage Iï¼šPreoperative therapy
      Capecitabine Plus Oxaliplatin With Bevacizumab is superior to Capecitabine Plus Oxaliplatin
      alines.

      Stage II: therapy after surgery Capecitabine Plus Oxaliplatin With Bevacizumab is superior to
      Capecitabine Plus Oxaliplatin alones after surgery for over 6 months in all.
    
  